n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, September 13th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

CVR Medical Corp. (CRRVF)

OTC Markets and MarketWatch reported on CVR Medical Corp. (CRRVF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

CVR Medical Corp. is engaged in an equal part joint venture (JV) with CVR Global, Inc. The JV operates in the medical industry centered on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology. Medical technology enterprise, CVR Medical is headquartered in Vancouver, British Columbia and the Company’s shares trade on the OTC Markets Group’s OTCQB.

The JV has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. The Carotid Stenotic Scan (CSS) is a unique tool that will be used to assess Carotid Arterial health in a way that is unavailable to the patient, healthcare provider, and the payor within the present system.

The CSS is a screening tool designed to detect and measure carotid arterial stenosis or occlusion for the purpose of identifying patients at risk for Ischemic Stroke. The CSS provides a synergistic tool that complements other stroke screening technology. The screening device is non-emissive and non-invasive. It does not require a certified technician and can be conducted in a few minutes.

The CSS has a per scan price point that is significantly advantageous as an initial screening tool versus the resource requirement associated with other technologies. CVR’s technology makes a connection between fluid flow and sub-sonic frequencies to ascertain the presence of arterial disease/blockage.   

CVR Medical is entering the Clinical phase of the development process. The final market version of the CSS is undergoing assembly and preparation for Pivotal Trials, which will then undergo submission for Food and Drug Administration (FDA) 510(k) clearance. 

CVR Medical reported in March of this year that it entered into a letter of intent (LOI) with CVR Global, Inc. to acquire an additional 10 percent interest of the "Joint Venture Business" from CVR Global's present 50 percent interest. The Joint Venture Business is held pursuant to, and governed by, the terms of the Joint Venture Agreement between CVR Global and CVR Medical.

Upon the closing of the Transaction, the Joint Venture Business and related assets will be transferred into a new corporate entity to be created for the continuing ownership and operation of the business.

Furthermore, in March, CVR Medical announced a partnership with ADCO Circuits. ADCO will be the exclusive provider of the custom circuit board inside the sensor of CVR Medical's Carotid Stenotic Scan (CSS) device. ADCO Circuits is a Michigan-based electronic design and manufacturing enterprise.

In April, CVR Medical announced an update on clinical trials of the Carotid Stenotic Scan (CSS), being conducted by way of the Jefferson Clinical Research Institute at Thomas Jefferson University under the supervision of Dr. David J. Whellan.

Dr. Whellan said, "Enrollment was initiated in early January. The prototype device, which is being operated in standard form, will soon be joined by its wireless charging technology, for which preparation has gone smoothly. The CSS, as a whole, has been widely praised for its ease of use. The training required was straightforward and allowed the coordinators to quickly gain experience and implement the study. Since its successful implementation, we have had steadily growing enrollment. We're looking forward to continuing our work with CVR."

Last week, CVR Medical advisory staff member Dr. Phillip J. Bendick, PhD, released a summarized report on data from the tertiary clinical trials for the Carotid Stenotic Scan (CSS) device at Thomas Jefferson University. His report views initial evaluations as successful, and confirms the device's value and efficiency.

This week, CVR Medical announced that an institutional research report was released by RB Milestone Group, LLC (RBMG). This report on CVR Medical titled "Revolutionizing the Vascular Diagnostics Market" can be found on the website at www.CVRMed.com or by contacting Trevor Brucato, Managing Director at RBMG. RB Milestone Group is a New York based consulting firm that CVR Medical engaged to provide the report. 

CVR Medical Corp. (CRRVF), closed Wednesday's trading session at $0.3428, up 1.21%, on 1,030,487 volume with 524 trades. The average volume for the last 60 days is 50,070 and the stock's 52-week low/high is $0.221/$0.5677.

Provision Holding, Inc. (PVHO)

GrowthPennyStocks, Penny Stock General, Shiznit Stocks, HotStockProfits, PennyDoctor, Stock Beast, RedChip, PennyStockLocks, Epic Stock Picks, Equity Observer, Value Penny Stocks, Wolf of Penny Stocks, Small Cap Firm, OTCMagic, MicroCapDaily, and StockRockandRoll reported on Provision Holding, Inc. (PVHO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Provision Holding, Inc., by way of its subsidiary, focuses on the development and distribution of intelligent interactive three-dimensional (3D) holographic display technologies, software, and integrated solutions for consumer and commercial centered application. These are chiefly for advertising and product merchandising markets. The Company’s initial line of display systems has proven to be ideally suited for indoor and outdoor point-of-sale (PoS), merchandising, and PoS related advertising venues. Provision Interactive Technologies, Inc. is a subsidiary of Provision Holding. Provision Holding is based in Chatsworth, California. 

Provision’s products include HoloVision displays and 3D Savings Center kiosks. These enable advertisers and customers to reach captive audiences in grocery stores, malls, convenience stores, gas stations, banks, as well as other retail sites. The Company’s proprietary 3D holographic display technologies give advertisers first-rate ability to direct customized content to a target audience. 

Provision's 3D holographic display systems represent a unique technology. This technology provides the projection of full color, high-resolution videos into space detached from the screen, without any special glasses. The Company has completed the development and prototype of its latest 3D holographic display system, the HL50.

The HL50 is its largest Holovision™ product. The design of it is for exhibitions and special events.  The HL50 uses Provision Interactive Technologies’ patented and award-winning 3D holographic technology.  It comes complete. This includes a media player and the Company’s proprietary software, HoloSoft™.  The HL50 can project visually stunning 3D holographic videos, detached from the screen, floating in space more than 40 inches outward. 
  
This past June, Provision Interactive Technologies announced that the Company entered into a multi-year partnership agreement with Discount Drug Mart, Inc. This partnership agreement is to install Provision’s proprietary 3D Savings Center kiosks inside Discount Drug Mart stores. The agreement represents the next major retail partnership for Provision.

Prosperity Investments, under its Joyful ATM brand, has entered into an agreement with Provision Interactive Technologies to integrate its 3D holographic display and coupon redemption platform into Joyful ATMs to boost in-store engagement and purchases at point-of-sale (PoS).

Greater than 48,000 Joyful ATM units are planned to undergo deployment across the U.S. and in another 68 countries over the next 72 months, at locations including banks, retailers, convenience stores, gas stations, and government buildings. Via the partnership, the ATMs will project 3D holographic advertising messages to attract customers to the unit. Upon the customer approaching the unit, they can redeem coupons for the advertised products that can be used right away, driving enhanced PoS activity.

Provision Holding, Inc. (PVHO), closed Wednesday's trading session at $0.05635, up 6.32%, on 103,307 volume with 9 trades. The average volume for the last 60 days is 338,302 and the stock's 52-week low/high is $0.041/$0.24.

GulfSlope Energy, Inc. (GSPE)

InvestorsHub, MarketWatch, Stockhouse, Morningstar, OTC Markets, Equity Clock, and Financial Times reported on GulfSlope Energy, Inc. (GSPE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

GulfSlope Energy, Inc. is an independent oil and natural gas company concentrating on exploring offshore U.S. Gulf of Mexico. The Gulf of Mexico has some of the lowest breakeven costs in the contemporary E&P industry. GulfSlope Energy utilizes 2.2 million acres of 3D seismic data to identify high quality exploration prospects. The Company’s team has a track record of discovering and developing multi-billion dollar projects internationally, with greater than 300 years of combined experience in the oil and gas exploration industry. Established in 2013, GulfSlope Energy is based in Houston, Texas.   

The 3D seismic data incorporates advanced processing technologies. These include beam and Reverse Time Migration (RTM) imaging. GulfSlope Energy integrates its comprehensive 3D seismic and geological databases. As a result it can identify leasing opportunities it believes have compelling characteristics pertaining to size, geological attributes, in addition to potential for economic returns. 

Regarding economics, GulfSlope indicates that large targets in shallow water offer substantial return potential. Furthermore, important infrastructure in the immediate area decreases costs and time to market.

GulfSlope’s portfolio has diversity in size, water depth, drilling depth, and risk profile. The Company’s target is the Shelf Miocene (2.2 MM Acres - 440 Blocks). Regarding GulfSlope’s Phase 1 Drilling Program, the Company has high-graded five prospects with mean unrisked resource potential of 623 MMboe. It is looking to capitalize on strategic advantages provided by exploration work to identify undervalued producing assets.  

Concerning the Company’s oil & natural gas exposure, GulfSlope Energy has more than 2 billion boe of net conventional recoverable resources. It has 23 lease blocks with 19 drilling prospects ranging from 30-280 MMboe. Regarding the prospects, the average size is 120 MMboe. GulfSlope Energy has an independent third party evaluation of prospect sizes. The prospects are consistent with deepwater Miocene evaluations discovered by major oil companies. 

GulfSlope’s current emphasis is on pre-drill operations. It has a hybrid operating model with a preference to operate. The Miocene Subsalt Play – La Shelf, has large resource potential; is low to moderate risk; has moderate drilling and development costs; has shortened times to initial production, and enhanced economics.

Today, GulfSlope Energy and Texas South Energy, Inc. (TXSO) (collectively, the Farmors) announced that they jointly executed an exclusive Letter of Intent (LOI) with a large global oil and gas company (the Partner) to jointly drill and develop the Farmors oil and gas prospects positioned offshore Gulf of Mexico.

Selected principal commercial terms of the farmout include the Partner earning a 75 percent working interest (WI) in each prospect by paying 90 percent of the exploratory costs and making a cash payment of $1.5 million to be split between the Farmors on a 73 / 27 percent basis.

GulfSlope will be the initial Operator of Record. The Company will retain a 20 percent WI for the subsalt prospects included in the first phase. Texas South will retain a 5 percent WI for the subsalt prospects included in the first phase.

GulfSlope Energy, Inc. (GSPE), closed Wednesday's trading session at $0.049375, up 107.46%, on 2,354,634 volume with 117 trades. The average volume for the last 60 days is 300,368 and the stock's 52-week low/high is $0.007/$0.04.

International Stem Cell Corp. (ISCO)

MissionIR, Tiny Gems, Marketbeat, StocksToBuyNow, Tip.us, and Serious Traders reported earlier on International Stem Cell Corp. (ISCO), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, International Stem Cell Corp. is a clinical stage biotechnology enterprise. The Company is developing stem cell-based therapies and biomedical products. Its concentration is on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The Company’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs).  

The hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. They offer the potential to create the first true stem cell bank, UniStemCell™.  International Stem Cell has its corporate office in Carlsbad, California. It has a research facility in Oceanside, California. 

International Stem Cell scientists have created the first parthenogenetic, homozygous stem cell line. This line can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages, and racial backgrounds with minimal immune rejection post transplantation. A relatively small number of hpSC lines could provide enough immune-matched cells to cover a large percentage of the world’s population. 

The Company produces and markets specialized cells and growth media for therapeutic research internationally through its subsidiary Lifeline Cell Technology (Frederick, Maryland) and stem cell-based skin care products by way of its subsidiary Lifeline Skin Care. 

International Stem Cell has demonstrated that ISC-hpNSC® can improve cognitive performance and motor coordination in rodents with traumatic brain injury. Also, ten pending patent applications covering internally-generated and in-licensed technologies have been issued as patents.  

The Company’s subsidiary, Lifeline Skin Care, has expanded its two core technology product lines through launching four new skincare products targeting retail and professional markets. In 2016, a new patent covering small molecule technology in skin care was issued to International Stem Cell in the United States 

Concerning the UniStemCell™ bank, it is the life science industry’s first collection of non-embryonic histocompatible human stem cells available for research and commercial use. The human leukocyte antigen (HLA) system represents antigens important for transplantation.

Last week, International Stem Cell reported that two more patients with Parkinson’s disease were successfully transplanted with the Company’s proprietary ISC-hpNSC® cells at the Royal Melbourne Hospital (RMH), in July and August, 2017. The two patients are part of the second cohort clinical trial being treated for Parkinson’s disease.

The two patients received a moderate dosage of ISC-hpNSC® cells using CT- and MRI-guided stereotactic brain surgery. The operations were successfully performed by the team of RMH neurosurgeons without complications. This Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranially transplanted into patients with moderate to severe Parkinson's disease.

International Stem Cell Corp. (ISCO), closed Wednesday's trading session at $1.60, up 4.58%, on 30,002 volume with 51 trades. The average volume for the last 60 days is 4,197 and the stock's 52-week low/high is $0.65/$2.50.

First Harvest Corp. (HVST)

OTC Markets, MarketWatch, Stockhouse, Barchart, 4-Traders, Marketwired, and Morningstar reported on First Harvest Corp. (HVST), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

First Harvest Corp. is a technology, media and mobile gaming platform with an emphasis on the cannabis industry. Headquartered in Tampa, Florida, the Company combines three of the fastest-growing business sectors. These are cannabis, social media, and mobile gaming. First Harvest is working on improving how legal cannabis advocates connect, communicate, as well as stay informed by way of digital media. First Harvest lists on the OTC Markets.

The Company’s platform encompasses mobile gaming, digital and social media, e-commerce sales, and education. First Harvest utilizes gaming and digital media as a sales platform with an inventive marketing strategy, which takes advantage of social and viral social mechanisms.

First Harvest’s platform connects mainstream advertisers to pro-legalization supporters of medical and therapeutic cannabis. Its Hemp, Inc. leverages the major growth in the mobile gaming and Smartphone markets, and the fast-developing medical and therapeutic cannabis industry. In essence, Hemp, Inc. is a business strategy, role-playing game. It centers on the modern cannabis culture. 

First Harvest has its Cannavoices. This is a member-based social media platform for subscribers to participate in an open forum with other pro-cannabis supporters in an interactive social media platform.

This past July, First Harvest announced that it entered into an asset purchase agreement. This agreement is to acquire the intellectual property (IP) rights and gaming software from Interactive Systems Worldwide, Inc. (ISWI). This includes its SportXction® System.

The SportXction System is a proprietary, real-time, interactive software system. It permits a user to make play-by-play wagers on a sporting event while the event is taking place. Wagering may be conducted online while viewing a live sporting event.

The online gaming or gambling worldwide market had a volume of $37.9 billion USD in 2015. Moreover, this figure was forecast to grow to $59.8 billion USD in 2020, according to the Statista's 2017 Sports Betting Report.

Last month, First Harvest announced its monetizing beta version launch of Ufly420. The enabling connectivity technology platform is alike to an UberEATS-style delivery application (app), providing on-demand legal cannabis delivery.

First Harvest anticipates full commercialization launch of the app in California on October 1, 2017. Company Management’s intention is to target all legal states that have legalized cannabis and also Canada and other countries as potential launch targets.

The Ufly420 business model allows for legal dispensaries and delivery services to upload and include their menus for free. The revenue model includes a small transaction fee paid by the customer and the dispensary. 

First Harvest Corp. (HVST), closed Wednesday's trading session at $8.50, up 41.67%, on 59,274 volume with 403 trades. The average volume for the last 60 days is 861 and the stock's 52-week low/high is $1.40/$6.00.

graphic

The QualityStocks
Company Corner

graphic
graphic

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.3635, up 3.86%, on 2,350,771 volume with 811 trades. The stock’s average daily volume over the past 60 days is 290,430, and its 52-week low/high is $0.069/$0.72.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. The publication, titled, "Cannabis Biotechs Taking Leading Stance in Global Marijuana Market," shines a light on biotech companies utilizing cannabis to treat medical conditions. To view the full publication, visit: https://www.networknewswire.com/cannabis-biotechs-taking-leading-stance-global-marijuana-market/

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

NetworkNewsWire Announces Publication Discussing Innovative Drug Developments in the Global Marijuana Market

InMed Files Provisional Patent for Biosynthesis of Cannabinoids

Biosynthesis Could Reduce Regulatory Hurdles for Cannabis Researchers -- CFN Media

AppSwarm, Inc. (SWRM)

The QualityStocks Daily Newsletter would like to spotlight AppSwarm, Inc. (SWRM). Today, AppSwarm, Inc. closed trading at $0.01, off by 4.76%, on 46,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 208,525 and its 52-week low/high is $0.002/$0.13.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions for business, today announces the online availability of its interview with AppSwarm, Inc. (OTC: SWRM), a technology development and incubation acceleration company that has evolved into a comprehensive partner to mobile game developers seeking success in a demanding marketplace. The interview can be heard at http://nnw.fm/swrm-interview-sept-2017

AppSwarm, Inc. (SWRM) is a technology development and incubation acceleration company that partners up with developers through joint ventures, royalty agreements, marketing partnerships, and outright purchase agreements. Focusing on the ever-growing mobile applications market, the company provides all the resources needed for engagement, retention, virality and monetization.

The global games market generated approximately $100 billion in revenues in 2016, but large global game companies have made it extremely difficult for smaller developers to achieve success in the marketplace. As a result, many great ideas aren't monetized. AppSwarm solves this problem by providing the funding and critical business expertise needed to successfully launch and market new applications.

Business applications is another area of focus for the company. Targeting small to medium sized businesses, AppSwarm will be developing and acquiring mobile application tools and platforms that increase productivity and security via data encryption, cloud storage, content management and delivery, digital payments, automation, and customer loyalty marketing solutions. Recent acquisitions made so far represent only a small example of future planned initiatives to develop and market tools for the business community.

Regardless of the target market, AppSwarm can help developers accelerate the success of their app through funding, technology and marketing expertise, as well as a unique eco system that accelerates user acquisition. The company is able to assist at any state of development with completion of concept, market analysis, business and financial management, direct sales and marketing, social game development to ensure correct product application and expedient deployment with cost efficiency.

Ron Brewer, CEO of the company, has accumulated extensive leadership in the technology sector and brings valuable knowledge gained as a Director of Southbridge Advisory Group for nearly 20 years. Ron's C-level experience includes merger & acquisition and post-acquisition turnaround in both the private and small-cap public sector. John Rabbit, director of finance, is a seasoned business veteran that has worked with Fortune 500 firms and served in CEO, COO and CFO positions for firms ranking from $5 million to $300 million in annual revenues. John was directly involved in numerous acquisitions and served in executive capacities for several multinational subsidiaries.

With a well-suited management team, multiple synergistic revenue streams, and diversified growth strategy, AppSwarm is well positioned in a steadily growing industry with countless opportunities for capitalization. Disclaimer

AppSwarm, Inc. Blog

AppSwarm, Inc. News:

NetworkNewsWire Releases Exclusive Audio Interview with AppSwarm, Inc. (SWRM)

AppSwarm, Inc. (SWRM) Engages NetworkNewsWire for Corporate Communications Solutions

AppSwarm Announces Acquisition of Multiplatform Games Developer and Publisher MediaPlay and the Creation of Two Divisions of AppSwarm, Inc.

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0209, off by 11.06%, on 3,394,199 volume with 101 trades. The stock’s average daily volume over the past 60 days is 1,983,565, and its 52-week low/high is $0.0077/$0.04.

Global Payout, Inc. (GOHE) is pleased to announce that its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC," the "Company"), has executed a Letter of Intent ("LOI") with BlazeNow, Inc., a majority owned subsidiary of MediaTechnics Corporation (OTC PINK: MEDT). As an advertising and data collection platform, BlazeNow connects cannabis-related businesses with patients and customers, and was called the "Yelp" of the cannabis industry by NY Daily News.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout's Moneytrac Technology Inc. Signs LOI with Renowned Marijuana Technology Company, BlazeNow, Inc.

Global Payout, Inc. Begins Company Audit with Intent of Filing Form 10-K and Becoming Fully Reporting Within 60 Days

NetworkNewsWire Announces Publication Highlighting Innovative Public FINTECH Companies

Bollente Companies, Inc. (BOLC)

The QualityStocks Daily Newsletter would like to spotlight Bollente Companies, Inc. (BOLC). Today, Bollente Companies, Inc. closed trading at $0.834, even for the day. The stock’s average daily volume over the past 60 days is 1,061 and its 52-week low/high is $0.20/$1.21.

Bollente Companies, Inc. (BOLC) is in the early stages of developing a diverse portfolio of companies, targeting disruptive technologies that positively impact the environment and emerging economies. Their current focus is on high-efficiency electric tankless water heaters, manufactured and sold under "trutankless", a division of Bollente, including a line of economy tankless water heaters sold under the Vero name. Units are available for both residential and commercial application.

The primary Bollente advantage is their use of advanced technology, superior to previous tankless systems, together with a growing U.S. and global market. Traditional water heaters are one of the costliest appliances to operate. The two primary energy sources used in U.S. homes are electric and natural gas, with less than half of U.S. homes having natural gas available. In addition, there are no significant electric whole home tankless manufacturers.

The U.S. Department of Energy now requires tanks of 55 gallons or more to have efficiency levels requiring expensive heat pumps to achieve. Bollente's trutankless electric tankless water heater employs specialized sensors for constant water temperature, solid state electronics, and proprietary software, resulting in one of the most efficient heat exchangers ever produced. The technology includes smart grid and home automation capabilities, remote control and monitoring, and even smartphone alerts. It also allows adjustable custom power management settings, so that users can further enhance energy usage and performance. It is now estimated that tankless heaters used in every home would save over $8 billion annually in the U.S. alone.

By maintaining 99 percent efficiency, Bollente's trutankless heaters use less energy than tank heaters, while providing the convenience of always-hot water. The system only uses power when there is demand, producing water to exact temperature, within one degree, even with sudden changes to input. Wireless apps allow for remote settings, notifications, and monitoring, and models are compatible with existing home automation and energy management systems. The technology also reduces size, for easy location, and the system's self-flushing design provides up to 20+ years of maintenance free operation, significantly reducing upkeep and replacement costs. This becomes an additional environmental benefit since roughly 8 million used water heaters are dumped in landfills every year.

Bollente has also announced the formation of Bollente International, Inc., a wholly-owned subsidiary, for the international production and sale of trutankless systems. Taking advantage of growing interest in their technology, Bollente International is working with an international manufacturing firm for the production and distribution of trutankless systems throughout Europe, Asia, Australia and New Zealand, with the first step being the testing and certification necessary to meet the various international standards.

Bollente has made electric tankless water heating compelling to a major consumer market, both in and outside the U.S., offering economic as well as operational efficiency and convenience, attractive to builders as well as to end consumers. Disclaimer

Bollente Companies, Inc. Blog

Bollente Companies, Inc. News:

Bollente Companies Increases Production and Distribution Capabilities for trutankless® with Global Manufacturing Partnership

Bollente Companies Increases Presence in Trending Segment of Commercial Construction with Its Smart trutankless Product Line

Award-Winning Luxury Builder Cullum Homes Makes trutankless® the Exclusive Water Heating Solution in its Communities

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.60, off by 7.15%, on 49,995 volume with 19 trades. The stock’s average daily volume over the past 60 days is 60,347 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. Announces Major Expansion of Operations with Launch and Adoption of Orthopedic Service Lines

ORHub, Inc. Signs National Sales Partner to Launch Transformative Medical Software in Major U.S. Markets

ORHub, Inc. Introduces Fourth Medical Software Service Line, Continuing Rapid Expansion Strategy

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Trader Power News
(NETE) +114.29%

2.

QualityStocks
(GSPE) +107.46%

3.

Penny Stock Titans
(TWOH) +52.50%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251